Crimson Publishers Publish With Us Reprints e-Books Video articles


Modern Approaches in Drug Designing

“Trojan” RNA Viruses Carrying PAK18 for Therapy of PAK1-Dependent Diseases

Submission: February 23, 2022; Published: September 08, 2022

ISSN : 2576-9170
Volume 3 Issue 5


Around 1980, several viruses were found to carry an oncogenic mutant of cellular genes such as a Tyrkinase called SRC and a G protein called RAS, eventually causing malignant trans-formation in chicken and mouse. Reversely, if we can manage to insert into viral genomes several known anti-oncogenes such as NF1, NF2, p53, and RB, in principle, we could suppress the growth or metastasis of cancers. On the recent advent of COVID pandemics, a brand-new idea using this RNA virus as a carrier of anti-pathogenic genes such as PAK1-blockers, to reverse the pathogenic process, has suddenly emerged. Here as an example, I briefly introduce a PAK1-blocker called “PAK18”, a peptide of 18 amino acids derived from the major pathogenic kinase “PAK1”, which could suppress cancers and many other PAK1-dependent diseases by blocking the interaction of PAK1 with its activator called PIX. The Genetically Modified (GM) COVID carrying the mRNA coding PAK18 can infect lung and platelet cells through its spike proteins, but cannot cause either fibrosis or thrombosis, because these pathogenic processes require PAK1. Instead, this GM virus mass-produces PAK18 in target cells and suppresses a wide variety of PAK1-dependent diseases, including immune-suppression, boosting B/T cells to produce antibodies against COVID, thus working as a COVID vaccine as well, and eventually promoting the longevity.

Keywords: PAK1; PAK18; COVID; PIX; Cancer; Fibrosis; Thrombosis

Get access to the full text of this article